Next Article in Journal
From the Sun to the Cell: Examining Obesity through the Lens of Vitamin D and Inflammation
Previous Article in Journal
Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 14
Issue 1
10.3390/metabo14010003
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Opinion

Analysis of Crude, Diverse, and Multiple Advanced Glycation End-Product Patterns May Be Important and Beneficial

by
Takanobu Takata
1,2,*,
Togen Masauji
2 and
Yoshiharu Motoo
3,*
1
Division of Molecular and Genetic Biology, Department of Life Science, Medical Research Institute, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan
2
Department of Pharmacy, Kanazawa Medical University Hospital, Uchinada 920-0293, Ishikawa, Japan
3
Department of Internal Medicine, Fukui Saiseikai Hospital, Wadanakacho 918-8503, Fukui, Japan
*
Authors to whom correspondence should be addressed.
Metabolites 2024, 14(1), 3; https://doi.org/10.3390/metabo14010003
Submission received: 2 November 2023 / Revised: 8 December 2023 / Accepted: 17 December 2023 / Published: 19 December 2023
(This article belongs to the Section Pharmacology and Drug Metabolism)
Browse Figures
Review Reports Versions Notes

Abstract

:
Lifestyle-related diseases (LSRDs), such as diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis, are a global crisis. Advanced glycation end-products (AGEs) have been extensively researched because they trigger or promote LSRDs. Recently, techniques such as fluorimetry, immunostaining, Western blotting, slot blotting, enzyme-linked immunosorbent assay, gas chromatography-mass spectrometry, matrix-assisted laser desorption-mass spectrometry (MALDI-MS), and electrospray ionization-mass spectrometry (ESI-MS) have helped prove the existence of intra/extracellular AGEs and revealed novel AGE structures and their modifications against peptide sequences. Therefore, we propose modifications to the existing categorization of AGEs, which was based on the original compounds identified by researchers in the 20th century. In this investigation, we introduce the (i) crude, (ii) diverse, and (iii) multiple AGE patterns. The crude AGE pattern is based on the fact that one type of saccharide or its metabolites or derivatives can generate various AGEs. Diverse and multiple AGE patterns were introduced based on the possibility of combining various AGE structures and proteins and were proven through mass analysis technologies such as MALDI-MS and ESI-MS. Kampo medicines are typically used to treat LSRDs. Because various compounds are contained in Kampo medicines and metabolized to exert effects on various organs or tissues, they may be suitable against various AGEs.

1. Introduction

Lifestyle-related diseases (LSRDs), including diabetes mellitus (DM), cardiovascular disease (CVD), and nonalcoholic steatohepatitis (NASH), are a global crisis, mostly in developing countries [1,2,3,4,5]. This is attributed to people consuming excess saccharides (e.g., glucose and fructose), proteins, and lipids. However, LSRDs were also known in ancient times, when only a few affluent individuals, such as those belonging to royalty or nobility, could afford to consume them excessively because saccharide-sweetened ingredients such as Gynostemma pentaphyllum (Thunb.) (Japanese name: amachazuru; Chinese name: jaogulan) were used in daily life [6]. Moreover, ancient Chinese medicine considered the concept of DM symptoms [7,8]. Advanced glycation end products (AGEs), which are generated from saccharides/their metabolites or derivatives and proteins, are associated with LSRDs [1,2,3,4,5,9]. Although AGEs have been investigated since the early 20th century, when the Maillard reaction was proven [9], their relationship with human health dates back to ancient times. AGEs have been analyzed using techniques such as fluorimetry [10], immunostaining [2,11,12], Western blotting [2,13], slot blotting [2,14,15,16], enzyme-linked immunosorbent assay (ELISA) [11,17,18], gas chromatography-mass spectrometry (GC-MS) [19], matrix-assisted laser desorption-mass spectrometry (MALDI-MS) [20], and electrospray ionization-mass spectrometry (ESI-MS) [21,22]. Researchers have investigated LSRDs and AGEs using these technologies. AGEs can be classified as intra- and extracellular AGEs [1,2]. Intracellular AGEs are generated in cells and can induce cell dysfunction and death [2,9,10,11,12,13,14]. Extracellular AGEs include (i) AGEs in body fluids (e.g., blood [2,10,11,14,17,18,23], saliva [24], and urine [17,19]) and (ii) dietary AGEs [9,25]. Dietary AGEs are generated in beverages and foods that are manufactured or cooked by heating. Because AGEs in the blood, saliva, and urine are released or leaked from organs, some researchers have investigated their potential as biomarkers against disease or organ dysfunction [11,17,18,19,23,24]. Extracellular AGEs can bind to receptors for AGEs (RAGE) and toll-like receptor 4 (TLR4) and induce cytotoxicity, including inflammation [26,27]. Researchers can analyze the molecular weights of AGEs, their structure, and the glycated amino acids in peptide sequences using the aforementioned technologies. In this article, we categorized the approaches for analyzing AGEs as (i) crude, (ii) diverse (types 1 and 2), and (iii) multiple AGEs (types 1 and 2) patterns. In the crude AGE pattern, one type of saccharide or its metabolites or derivatives generate certain AGE structures in cells [2,28]. In the type 1 diverse AGE pattern, some AGE structures can be modified against one type of protein [29,30,31], whereas in type 2, one type of AGE structure can be modified using certain proteins [32]. In the type 1 multiple AGE pattern, some AGE structures are modified by one protein molecule [31], whereas in type 2, one AGE structure is modified by more than two proteins via intramolecular covalent bonds [2,31]. Using this approach towards the relationships between AGE structure and proteins, the diversity and multiplicity of AGEs can be explored, and new targets of investigation can be discovered for researchers who aim to find cures or prevent AGE-associated diseases.
Kampo medicines are traditional medicines that were introduced from China but developed uniquely in Japan from the fifth to the nineteenth centuries [33,34,35]. Modern Kampo medicines are produced from extracts by pharmaceutical companies governed by several national laws in Japan since approximately 1950 [35,36]. The Japan Society for Oriental Medicine has published “Standards of Reporting Kampo Products” to provide researchers with information on Kampo products in English [37]. Kampo medicines have been subjected to randomized controlled trials to obtain clinical evidence [38,39]. For Japanese industry, academia, and government, promoting “Kampo medicines for cancer supportive care” is one of the goals for the future of Kampo medicines [40,41,42]. Despite numerous efforts, the components of Kampo medicines have not yet been identified [43,44,45]. These medicines generate various metabolites that affect certain organs [42,43,44,45]. Therefore, Kampo medicines may inhibit the generation of intracellular AGEs, suppress AGE-RAGE/TLR4 signaling, and cure and prevent LSRD triggered or promoted by AGEs.

2. Techniques for Analyzing AGEs

2.1. Fluorimetry

AGEs fluoresce, and measuring this phenomenon is very simple and useful because it enables researchers to detect and understand AGE structure [10]. However, other fluorescent substances may also be considered.

2.2. Immunostaining

The benefit of immunostaining is that AGE accumulation in cells or tissues can be visualized [2,11,12,46]. Moreover, AGE-positive areas can be enumerated. Kehm et al. measured arg-pyrimidine- and pentosidine-positive areas in the pancreatic islets (AGEs area/pancreatic islets) [11], while van Heijist et al. revealed that heat shock protein (HSP) 27 and arg-pyrimidine were co-located in the immunostaining images of squamous cell carcinoma tissue in patients with non-small cell lung cancer; arg-pyrimidine-modified HSP27 was also located in this tissue [46]. Considering the characteristics that require anti-AGE antibodies, immunostaining [2,11,12,46], Western blotting [2,13,32], slot blotting [2,14,15,16], and ELISA [10,17,18] can be grouped together. Moreover, if the structure of AGEs remains unclear (e.g., AGEs with an unknown structure generated from methylglyoxal and bovine serum albumin [BSA] [47]), it can still be examined using anti-AGE antibodies produced against the AGEs for the antigen. However, this method has drawbacks. Ikeda et al. researched the monoclonal and polyclonal anti-Nε-carboxymethyl-lysine (CML) antibodies [48,49]. They revealed that some anti-CML antibodies could probe non-CML epitopes in proteins. Therefore, researchers may not completely assess the regulation of AGEs with only anti-AGE antibodies, which causes non-specificity in the results obtained from non-mass spectrometry analyses such as immunostaining, Western blotting, slot botting, and ELISA. In these analyses, researchers may require a control that has the epitope without the targeted AGEs and can be probed using anti-AGEs antibodies.

2.3. Western Blotting

In Western blot analysis, AGE-modified proteins on the membrane are detected by chemiluminescence or fluorescence, and the molecular weight of each AGE-modified protein is visualized [2,13,32]. Previously, we reported one type of glyceraldehyde-derived AGEs (GA-AGEs), which some researchers refer to as toxic AGEs (TAGE), in a human pancreatic ductal cell line (PANC-1) treated with glyceraldehyde [2]. The structure of TAGE was shown to contain a 1,4-dihydropyrazine ring [5]; however, it has not been proven definitively. TAGE-modified proteins have been detected using polyclonal antibodies [2]. Mastrocola et al. fed high-fat high-sugar to C57 and OB/OB mice and quantified CML- and Nε-carboxyethyl-lysine (CEL)-modified proteins in murine skeletal muscle based on their detected bands [32].

2.4. Slot Blotting

Slot blot analysis is generally performed to quantify AGEs [2,14,15,16]. In 2017, we developed a novel slot-blot method with the following characteristics: (i) a lysis buffer containing tris-(hydroxymethyl)-aminomethane (Tris), urea, thiourea, and 3-[3-(cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS), and (ii) polyvinylidene fluoride (PVDF) membranes [2]. We considered that this lysis buffer could promote the ability of samples containing AGE-modified proteins to suitably probe the PVDF membrane [16]. We analyzed TAGE and 1,5-anhydro-D-frucotose-derived AGEs (1,5-AF-AGEs) in cells and tissues using TAGE-modified BSA and 1,5-AF-AGEs-modified BSA as standards [2,14,15,16,50]. Bronowica-Szyełko et al. analyzed serum methylglyoxal-derived AGEs (MGO-AGEs) using slot blotting [17]. Although they selected a PVDF membrane, no reagents were added to the serum sample. Dot blot analysis is similar to slot blot analysis, differing only in the dilatation of the area on the membrane [51].

2.5. ELISA

The concept of ELISA is similar to that of slot blotting, i.e., samples are probed into 96-well microplates, and AGEs are identified and quantified using anti-AGE antibodies [11,17,18,23,24,52]. Samples, such as plasma [11], serum [17,23], saliva [24], urine [18], and tissue lysates [52], have been analyzed. Ruiz-Meana et al. quantified CML-modified proteins in human cardiac tissue using CML-modified BSA as a standard [52]. Although many targets in the samples were AGE-modified proteins, Kashiwabara et al. quantified a free-type of pentosidine in urine, which is a unique challenge considering the difficulty of producing antibodies against low molecular weight compounds [18].

2.6. GC-MS

GC-MS has been used to perform absolute quantification of free-type AGEs [19,53,54,55]. However, AGE-modified proteins cannot be detected and analyzed because the conditions of GC-MS analysis (i) include a sample molecular weight range of 100–1000 Da, (ii) samples must be modified to their ester derivatives, (iii) samples should be heated and degraded at 250–500 °C, and (iv) the molecular weight of the target must be proven [19,56]. Therefore, AGE-modified proteins must be hydrolyzed to obtain free-type AGEs and undergo esterification to obtain free AGE-ester derivatives (Figure 1) [19].
Baskai et al. performed the absolute quantification of CML and CEL using stable isotope-substituted CML and CEL as internal standards. The CML and CEL in the samples could be quantified because their retention times were the same and the mass ion peaks (m/z) differed [19,53,54,55].

2.7. MALDI-MS and ESI-MS

MALDI-MS and ESI-MS have promoted the investigation of proteomics since approximately 1990, and these instruments can be connected to liquid chromatography (LC) to produce LC-MALDI-MS and LC-ESI-MS [57,58,59]. Researchers have widely used LC-ESI-MS because of the ease of sample injection. Based on the peptide sequence database, peptide ion peaks and their fragment ion peaks have been calculated, and proteins have been identified [57,58,59], contributing to the investigation of AGEs. MALDI-MS/ESI-MS and nuclear magnetic resonance (NMR) have been used to identify the structure of free-type AGEs, such as 3-deoxyglucosoine-derived lysine dimer (1,3-di(Nε-lysino)-4-2-(2,3,4-trihydroxybutyl)-imidazoium salt) (DOLD), glyoxal-lysine dimer (1,3-di(Nε-lysino) imidazolium salt) (GOLD), methylglyoxal-lysine dimer (1,3-di(Nε-lysino)-4-methyl-imidazolium salt) (MOLD), vesperlysne A, glucosepane, tetrahydropyrimidine, glycolaldehyde-pyridine, and crossline [60,61,62]. Although novel free-type AGEs have been identified by analyzing individual ion peak data using MALDI-MS/ESI-MS and NMR spectrum data, the structure, ion peak pattern, and degradation of free-type AGEs have been analyzed and their data inputted into databases using only MALDI-MS/ESI-MS. Based on the development of technology for free-type AGE analysis, free-type AGEs have been quantified in various samples [21,63,64,65]. However, when AGE-modified proteins in samples are subjected to acid hydrolysis (e.g., hydrochloric acid), free-type AGEs can be obtained for quantification (Figure 2) [21,63,64,65].
Analyzing AGE-modified peptides is challenging because typical databases do not contain glycation information, although information on methylation and acetylation is available [57,58,59]. When researchers analyze proteins, peptides can be identified using databases that can predict the possibility of methylation and acetylation. Therefore, numerous peptides and proteins can be identified based on peptide information. Although information on glycosylation is normally unavailable, this modification can be removed from peptide sequences during ionization and does not inhibit peptide identification [59]. In contrast, glycation cannot be removed from peptides during the ionization step of MALDI-MS/ESI-MS analysis, and its information is unavailable; therefore, AGE-modified peptides cannot be identified (Figure 3) [57,58,59]. However, many researchers have attempted to analyze AGE-modified proteins and succeeded in identifying amino acids (e.g., lysine and arginine) in AGE-modified proteins by comparing the ion peaks of normal and glycated peptides [22,30,31,51,66,67,68]. If researchers can input information on AGE modification against peptides in databases, AGE-modified proteins can be efficiently identified (Figure 3) [28].

3. Intra-/Extracellular AGEs and LSRDs

3.1. Intracellular AGEs and LSRDs

Previously, we reported that PANC-1 cells and a human pancreatic islet β cell line 1.4E7 underwent TAGE-induced cell death, and microtubule-associated protein light chain 3 (LC)-I, LC3-II, and p62 in 1.4E7 cells were downregulated [2,14]. In addition, Suh et al. reported that methylglyoxal treatment of a murine pancreatic islet β cell line (RIN-m5F) generated MGO-AGEs, induced cell death, and reduced insulin secretion [47]. Ohno et al. demonstrated that glucoselysine and CML accumulate in the eye lenses of diabetic Wistar rats [21], and Bellier et al. reported that MGO-AGEs induce DM and cancer [22]. Furthermore, Kehm et al. revealed that a carbohydrate-free, high-fat diet and carbohydrate-rich diet (CRD) fed to New Zealand obese (MZO) mice (obese, diabetes-prone model mice) resulted in the considerable accumulation of argpyrimidine and pentosidine in the pancreatic islets [11]. Ruiz-Meana et al. found that CML-modified proteins accumulate in murine cardiac tissue and promote senescence in vivo [52], and we reported that intracellular TAGE may induce the death of normal human cardiac fibroblasts in vitro [15]. Mastrocola et al. reported that CML- and CEL-modified proteins accumulated in the skeletal muscle of OB/OB mice fed a high-fat, high-sugar diet, and their AGEs might be associated with myosteatosis [32]. We showed that generating 1,5-AF-AGEs induces cell death in a human hepatic cell line (HepG2) [50]. Based on these investigations, we hypothesized that intracellular AGEs may be associated with LSRDs, including DM, cancer, CVD, sarcopenia, and NASH.

3.2. Extracellular AGEs and LSRDs

3.2.1. AGEs in Fluids and LSRDs

Intracellular AGEs are generated in various cells and released or leaked into fluids (e.g., blood, saliva, and urine) as extracellular AGEs [10,11,17,18,19,23,24]. These AGEs can induce cytotoxicity, thereby including inflammation, because RAGE and TRL4 are expressed on the surfaces of various cells [1,11,26]. Furthermore, researchers have attempted to show that AGEs in the fluid correlate with the onset/progression of specific diseases, proving that AGEs could be biomarkers for these diseases [11,18,19,23,24,69,70,71]. The most beneficial and authentic biomarkers are (i) generated in specific organs and (ii) detected upon disease onset/progression, or organ dysfunction [72,73,74,75]. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are beneficial biomarkers of liver dysfunction, including nonalcoholic fatty liver (NAFL) and NASH, because high levels of ALT and AST are produced in the liver, unlike in other organs [72,73]. Creatinine kinase (CK) is a biomarker of heart dysfunction, for example, CVD [74,75]. CK in the blood increases when cardiomyocytes die due to CVD or is released from skeletal muscle during strenuous exercise. Although many AGEs can be generated/accumulated in certain organs, AGE has not been conclusively proven as a disease biomarker. However, Kehm et al. reported that plasma CML increased in MZO mice fed a CRD [11], and Kuang et al. reported increased plasma CML in patients with DM [69]. Notably, Kato et al. simultaneously analyzed four AGEs [CML, CEL, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine (5-hydroxy-5-methylimidazolone) (MG-H1), and Nω-carboxymethyl-arginine (CMA)] in the serum of nephropathy patients using LC-ESI-MS and showed that MG-H1 dramatically increased relative to the other three AGEs [70]. Lirwinowicz et al. determined the structure of a synthetic, melibiose-derived AGE (MAGE) and showed that MAGE in plasma correlated with NASH in a clinical study [71]. Although the structure of TAGE remains unclear, serum TAGE levels are associated with DM, CVD, NASH, infertility, cancer, and Alzheimer’s disease [5] and may be rare biomarkers with utility in determining the risk of various LSRDs.

3.2.2. Dietary AGEs and LSRDs

AGEs are produced in beverages and foods because of the presence of saccharides (e.g., glucose and fructose) and proteins, and heating treatment during manufacturing or cooking induces the Maillard reaction [1,25,76,77]. Because they can combine RAGE and TRL4 [78], AGEs may induce cytotoxicity via the dietary AGEs-RAGE/TLR4 axis. Based on the “Takayama Study”, Wada et al. suggested that CML, a dietary AGE, was significantly associated with an increased risk of male cancer [25]. Chen et al. focused on three AGEs, CML, CEL, and MG-H1, which are harmful to human health (e.g., oxidative stress and inflammation in the gut) [76]. Notwithstanding, we have focused on the relationship between dietary AGEs and oral, esophageal, and gastric epithelial cells [1]. RAGE is expressed on oral [79,80], esophageal [81], and gastric epithelial cells [82], and TLR4 is expressed on oral [83], esophageal [84], and gastric epithelial cells [85]. Because these epithelial cell types are exposed to air and direct physical contact with dietary AGEs, the dietary AGEs-RAGE/TRL4 axis may appear.

4. Categories of Free-Type AGEs Based on Original Saccharides and Their Metabolites/Derivatives

Until the beginning of the 21st century, seven categories of free-type AGEs were established: glucose-derived AGEs (Glc-AGEs, AGE-1), GA-AGEs (AGE-2), glycolaldehyde-derived AGEs (AGE-3), MGO-AGEs (AGE-4), glyoxal-derived AGEs (GO-AGEs, AGE-5), 3-deoxyglucosone-derived AGEs (3DG-AGEs, AGE-6), and acetaldehyde-derived AGEs (AA-AGEs) [1,5,9,86]. These groups were named based on the original saccharides and their metabolites/derivatives, which originated from the free-type AGE structure. However, subsequent research has changed the categorization of AGEs, owing to the development of various technologies for analyzing AGE structures [1,19,20,21,22,60,61,62]. Some reports indicate that glyceraldehyde-derived pyridinium (GLAP) [87,88,89], trihydroxy-triosidine [90], lys-hydroxy-triosidine [90], arg-hydroxy-triosidine [90], triosidine-carbaladehyde [90], MG-H1 [91], and argpyrimidine [92] have been generated from glyceraldehyde in vitro (categorized as GA-AGEs), although MG-H1 and argpyrimidine have been categorized as MGO-AGEs [93,94,95,96]. In contrast, Basakal et al. used GC-MS to reveal that CML, which had not been categorized as an MGO-AGEs, was generated from methylglyoxal in vitro [55]. Wang et al. reported that CML-modified proteins in a rat cardiomyocyte cell line (H9c2) treated with methylglyoxal increased, as shown by Western blotting [97]. Litwinowicz et al. classified the MAGE that they synthesized as AGE-10 [71]. The categories of MGO-AGEs and GA-AGEs may change in the future (Figure 4).

5. Crude AGE Pattern

We focused on the generation and accumulation of some types of AGEs from one type of saccharide metabolite/derivative (e.g., glyceraldehyde) in cells (Figure 5). We named this phenomenon the crude AGE pattern. Various AGEs that originate from the same compound may induce cytotoxicity and cell death. Previously, we reported that TAGE is generated and accumulated in PANC-1 cells treated with 1, 2, and 4 mM glyceraldehyde for 24 h via cell immunostaining, Western blotting, and slot blotting with a polyclonal anti-TAGE antibody [2]. However, we did not investigate the possibility that other types of AGEs may have been generated. Accordingly, Senavirathana et al. treated PANC-1 cells with 1, 2, and 4 mM glyceraldehyde for 48 h under conditions similar to those of our study and revealed that the cells generated and accumulated GLAP, argpyrimidine, and MG-H1 (Figure 5) [28]. Their analysis identified and quantified GLAP-, MG-H1-, and argpyrimidine-modified proteins by ESI-MS but not by Western or slot blotting with antibodies. Furthermore, they succeeded in proving that glyceraldehyde could produce three types of AGEs, although they did not investigate the possibility that TAGE might be generated. We believe that the study by Senavirathana et al. provides important data verifying the crude AGE pattern [28]. Notably, they showed that the ratio of GLAP, MG-H1, and argpyrimidine differed at different concentrations, although the incubation time for the glyceraldehyde treatment of PANC-1 was the same. These phenomena may be important because they reveal the conditions or pathways for generating each AGE structure. Furthermore, GLAP, MG-H1, and argpyrimidine might be associated with cytotoxicity and cell death, though we considered that only TAGE induced these phenomena [2,28]. However, we might have to focus on the possibility that glyceraldehyde generated various types of AGEs and induced death/dysfunction in cells.

6. Diverse AGE Pattern

6.1. Type 1 Diverse AGE Pattern

The type I diverse AGE pattern concerns AGE structures that can be modified in one type of protein (but one molecule of protein) (Figure 6). Although this pattern should be predictable based on the crude AGE pattern, this is difficult to prove owing to insufficient technology.
Norkin et al. treated recombinant human HSP90 with methylglyoxal and performed immunoprecipitation during production, which was analyzed by Western blotting using anti-MG-H1 and anti-argpyrimidine antibodies, with positive bands being detected [29]. Although this study suggested that MG-H1 and argpyrimidine were modified with some of the same peptide sequences as HSP90, we were unable to prove the type 1 diverse AGE pattern. Researchers cannot prove this pattern using antibodies alone, and mass spectrometry is required. Compared with only free-type AGEs, which are able to be analyzed with GC-MS [19,53,54,55], MALDI-MS and ESI-MS are suitable for analyzing AGE-modified proteins [21,30,31,63,64,65]. Although MALDI-MS/ESI-MS equipment and their databases are appropriate to prove the type 1 diverse AGE pattern, they must detect the appropriate AGE-modified peptides, which is difficult. Oya-Ito et al. successfully detected an appropriate AGE-modified peptide using LC-MALDI-MS [31]. They treated recombinant human HSP27 and phosphorylated HSP27 (p-HSP27) with methylglyoxal; their analysis revealed 22 and 23 AGE-modified peptides in HSP27 and p-HSP27, respectively. Furthermore, they revealed that some AGE types (e.g., HG-M1 and argpyrimidine) were modified at the same amino acid residue in the same sequence [31]. These data prove the type I diverse AGE pattern; we have shown some of the data in Figure 7. Two types of “HGYISRCFTR (131–140)” in HSP27, HG-M1 or argpyrimidine, were detected (Figure 7a). Although R (135) and R (139) were present in this sequence, HG-M1 and argpyrimidine were only modified at R (135). In “SRAQJGGPEAAR (187–198)”, R (188) was modified with MG-H1 or arg-pyrimidine (Figure 7b). Based on the investigation by Oya-Ito et al., we consider that the type I diverse AGE pattern can be proven.

6.2. Type 2 Diverse AGE Pattern

The type II diverse AGE pattern refers to a type of AGE structure that can be modified by some types of proteins (Figure 8). This has generally been detected using Western blotting through sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) (SDS-PAGE) [2,32,97]. This pattern was easily proven by examination using an anti-AGE antibody because the molecular weight and isoelectric point of each AGE protein were different. In contrast, Papadatki et al. [97] reported methylglyoxal modification of actin and myosin using LC-ESI-MS.

7. Multiple AGE Pattern

7.1. Type 1 Multiple AGE Parttern

We named the type I multiple AGE pattern because some types of AGE structures are modified by one protein molecule (but not one type of protein) (Figure 9). Although this pattern should be predictable based on the crude and type I diverse AGE patterns, analyzing this problem using more than one type I diverse AGE pattern is challenging. When AGE-modified proteins are used for tryptic diagnosis and their peptides are analyzed using MALDI-MS or ESI-MS, the peptides modified with more than two AGE structures should be detected (Figure 9).
Although this condition is challenging to achieve, Oya-Ito et al. used MALDI-MS to obtain two MG-H1 modified peptides, “SPAVAAPAYSRALSRQJSSGVSE (65–87)” and “IRHTADRWR (88–96)” in recombinant human HSP27 treated with methylglyoxal (Figure 10) [31]. Their data were suitable and sufficient to prove the type I multiple AGE pattern. Two MG-H1s modified R (75) and R (79) in the same peptide, and two MG-H1s modified R (89) and R (94) in HSP27.

7.2. Type 2 Multiple AGE Pattern

The type II multiple AGE pattern involves modification of the AGE structure in more than two proteins via intermolecular covalent bonds (Figure 11). The AGE structure, which can combine more than two amino acid residues in the protein (e.g., TAGE [5], DOLD [60], GOLD [60], MOLD [60], glucosepane [60], vesperlysine A [60], crossline [60], and triosidines [90]), can generate a complex of more than two proteins. This protein complex is produced via covalent bonds without disulfide bonds, and their covalent bonds cannot be destroyed when analyzed by Western blotting using SDS-PAGE. We reported that PANC-1 cells were treated with glyceraldehyde, and the high molecular bands of HSP27, HSP70, and HSP90β were detected with Western blot analysis using SDS-PAGE [2]. These data suggested the possibility that the structure of GA-AGEs generated the homo- or heterodimer of HSPs, though we were unable to prove the real chimerical structure of GA-AGEs. GLAP [87], MG-H1 [91], and argpyrimidine [92] can combine one amino acid residue but not more than two. Therefore, they could not generate the complex of proteins, though they were generated by glyceraldehyde in PANC-1 cells [28]. In contrast, TAGE [5] and some types of triosidines [90] were generated from glyceraldehyde and can combine more than two amino acid residues. They might generate a complex of proteins.
The AGE structure produces both intra- and intermolecular covalent bonds (Figure 12). Therefore, one type of AGE structure generates a complex of more than two proteins, while the other type may be modified via intramolecular covalent bonds (Figure 12). Nevertheless, researchers cannot prove that only one type of AGE structure generates a complex of some proteins (combining more than two proteins) with only anti-AGE antibodies because anti-AGE antibodies cannot recognize the difference between intra- and intermolecular covalent bonds in the AGE structure. Although the anti-D2 antibody recognized the “D2 type of AGEs structure and amino acids (4 and 13)” in protein A, the D1 type AGEs structure contributed to the intermolecular covalent bond between protein A and B. Therefore, while the anti-D2 antibody recognized this complex, we cannot state conclusively that D2-type AGEs contributed to producing the complex of proteins A and B (Figure 12).
MALDI-MS or ESI-MS analyses cannot accurately identify the one type of AGE structure that combines more than two proteins. Peptide sequences without AGE modification were identified based on the normal database using MALDI-MS/ESI-MS analysis (Figure 13). However, the AGE structure of the complex of peptides originating from more than two proteins could not be identified, although the molecular weight of the AGE modification (e.g., D1 in Figure 13) was automatically inputted into the database. If AGE structures combine with one protein residue, such as CML, CEL, or MG-H1, the molecular weight and mass ion peak of the peptide modified with these AGE structures can be calculated (Figure 6, Figure 7, Figure 9, and Figure 10). However, this technology can be employed only if one type of protein is targeted for analysis. Because we could not predict the molecular weight of the complex of the AGE structure and peptides with more than two origins, the calculated molecular weight (and m/z) could not identify the amino acid sequences and AGE structure (Figure 13).

8. Investigation of AGEs and LSRDs Based on the Three Patterns

Current technologies, including manufacturing anti-AGE antibodies, GC-MS, MALDI-MS, and ESI-MS, can analyze the structure of AGEs (free types of AGEs), their modified amino acid residues, and proteins that are modified with the AGE structure. Based on the development of an analysis method for AGEs, we described the crude, diverse, and multiple AGE patterns. We believe that these patterns can focus on the relationship between AGEs and LSRDs (e.g., DM, CVD, NASH, infertility, cancer, and Alzheimer’s disease) at the macro- to micro-levels. Although simple examination systems should be constructed for basic investigation, several researchers have made novel discoveries, and the range of AGEs available can be expanded. Therefore, investigating the relationship between AGEs and LSRDs may provide new research directions. The crude AGE pattern was proven in cellulosis and in vitro (Figure 5) [2,28]. If the regulation of one type of AGE was associated with the death/dysfunction of cells, other types of AGEs, including those that have been analyzed, might induce these phenomena. In contrast, one type of AGEs might induce the death/dysfunction of cells by cooperating with other types of AGEs. Multiple studies that many researchers have performed can confirm the link between individual AGEs and LSRDs, if such a correlation exists. This possibility applies to the diverse and multiple AGE patterns. If researchers observe that an AGE structure is modified in an individual protein, revealing its dysfunction, another type of AGE structure may be modified against it to inhibit its activity (Figure 6 and Figure 9). If one type of AGE-modified protein showed dysfunction or harmed the cell, other proteins modified with the same type of AGE structure did not show abnormal activity (Figure 8). In contrast, one type of AGE structure may promote dysfunction or harm the cell by cooperating with other types of AGE structures, whereas some types of structure may trigger/promote LSRDs simultaneously. The most difficult issue to approach is the type II multiple AGE pattern (Figure 11, Figure 12 and Figure 13). The investigation based on the type II multiple AGE pattern remains inconclusive. These issues may apply to both intracellular and extracellular AGEs. On the AGEs-RAGE/TRL4 axis, the effects of various AGEs may be detected. When researchers investigate the treatment of LSRDs triggered or promoted by various extracellular, body fluid, or dietary AGEs based on crude, diverse, and multiple AGE patterns, analyzing their mechanisms is difficult. However, differentiating between these patterns may be important and beneficial for researchers.

9. Effects of Kampo Medicines on Intra- and Extracellular AGEs

Researchers investigating the treatment and prevention of LSRDs promoted or triggered by various AGEs do not agree conclusively on the medicines to be employed against various AGEs. However, we believe that Kampo medicines containing crude drugs may be beneficial against various AGEs. Modern extracts of Kampo medicines are manufactured, and the quality control of some beneficial components of Kampo medicines is ensured by several national laws in Japan (Figure 14) [35,36]. The numerous compounds present in Kampo medicines cannot be detected, even using three-dimensional HPLC analysis [98,99,100]. Various compounds are ingested, digested in the stomach, absorbed into the small intestine, and metabolized in the liver [1]. These processes produce metabolites that are transported to organs or tissues, such as the mouth, small and large intestines, brain, and skeletal muscle, and they can undergo further metabolism and non-enzymatic reactions (Figure 15) [43,44]. Although all compounds in Kampo medicines have not been identified, the utility of Kampo medicines in treating diseases or inducing beneficial effects against syndromes has been investigated [42,45]. Kampo medicines have been used to treat LSRDs such as DM [101,102] and NASH [103,104]. Yamakawa et al. reported that Bofutstushosan (Chinese name: Fang-Feng-Tong-Sheng-San) contained various low-molecular compounds and insist it may be useful for the treatment of obesity [105]. Uneda et al. revealed that Bofutsushosan significantly reduced body mass index (BMI) in a clinical study [106]. Because BMI was reduced, we consider that Bofutsushosan was able to improve obesity. Although Seitai (Chinese name: Qing-Dai) was known as the crude drug that had therapeutic effects for ulcerative colitis, which may be associated with LSRDs, it improved the pulmonary arterial hypertension of the patients with ulcerative colitis [107,108]. Kampo medicines may inhibit the generation of intracellular AGEs, block the extracellular AGEs-RAGE/TRL4 axis, and suppress phenotypes via AGEs-RAGE/TRL4 axis signaling. Ańanco et al. [109] and Yadav et al. [110] focused on low molecular weight compounds that are present in natural products (e.g., catechin [109], epicatechin [109], epicatechin gallate [109], gallic acid [110], and gallotannin [110]) as they might inhibit AGEs generation and suppress AGEs-RAGE/TRL4 axis signaling. In contrast, Zhi et al. revealed that Jin-Si-Wei (Japanese name: Shikunshito), which consists of Ginseng, Atracylodos macrocephala, Poria cocos, and Glycyrrhiza uralensis, decreased amyloid β1–42, amyloid precursor protein, and RAGE in the brains of APPswe/PS1ΔE9 transgenic mice [111]. Because Jin-Si-Wei reduced RAGE, it may suppress AGEs-RAGE axis signaling and improve Alzheimer’s disease. Liu et al. also reported the potential of the decoction of Angelica sinensis, Zingiberis Rhizoma Recens, and Mutton (Japanese name: Toukisyoukyouyounikuto. Chinese name: Dang-Gui-Sheng-Jiang-Yang-Rou-Tang) to inhibit pro-inflammatory factors through AGEs-RAGE axis signaling in diarrhea-predominant irritable bowel syndrome [112]. Although Toukisyoukyouyounikuto is not contained in modern Kampo medicines because they were not described in the current Japanese Pharmacopoeia by several national laws in Japan [33,34,35,36], they may be focused on the effects of inhibition of AGEs-RAGE axis signaling in the future. The potential of some Kampo medicines to suppress AGEs-RAGE axis signaling has been revealed, though researchers have not made the mechanisms sufficiently clear because Kampo medicines contain various compounds that would be metabolized and treated with non-enzymic reactions (Figure 15) [43,44]. On the contrary, the mechanisms by which each Kampo medicine or Crude drug suppresses the generation of individual AGEs (e.g., CML, CEL, and CMA) remain unclear. However, Ban et al. reported that the aqueous extract of Trapa biopiosa Roxb., a crude drug, inhibited MG-H1 generation from ribose-derived gelatin in vitro [113]. Tominaga et al. reported that the aqueous methanol extract of Drosera tokainsis inhibits the generation of CML and CMA from ribose-derived gelatin in vitro [114]. Although Kampo medicines should generally be administered orally and their compounds are metabolized to exert effects in the human body, previous research provides important background [43,44,45,115]. Studies in which the characteristics of Kampo medicines are reproduced must clarify their effects against intra- and extracellular AGEs in vitro and in vivo [1]. Although the mechanisms underlying the various effects of Kampo medicines have not been sufficiently elucidated, they may be beneficial against various types of AGEs because each compound and its derivatives can act against various types of AGE structures.

10. Conclusions

In the present review, we introduced the crude, diverse, and multiple AGE patterns. We believe that these patterns suggest the need to perform more complex analyses to reveal the structure of AGEs, AGE modifications in peptide sequences, and novel perspectives on the investigation and treatment of LSRDs associated with AGEs. Furthermore, we believe that Kampo medicines may be beneficial against various AGEs that trigger or promote LSRDs. Therefore, analyzing these patterns of AGEs may be important and beneficial.

Author Contributions

Conceptualization T.T.; Methodology T.T. and Y.M.; Writing—Original draft preparation T.T., T.M. and Y.M.; Writing—Review and Editing T.T., T.M. and Y.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by JSPS KAKENHI (grant number JP21K11607 (T.T.)).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AF-AGEsAnhydro-D-fructose advanced glycation end-products
AGEsAdvanced glycation end-products
ALTAlanine aminotransferase
Arg-PArgpyrimidine
ASTAspartate aminotransferase
BSABovine serum albumin
CELNε-carboxyethyl-lysine
CKCreatinine kinase
CMANω-carboxymethyl-arginine
CMLNε-carboxymethyl-lysine
CVDCardio vascular disease
DMDiabetes milieus
DOLD3-deoxyglucosoine-derived lysine dimer
ELISAEnzyme-linked immunosorbent assay
ESI-MSElectrospray ionization-mass spectrometry
GA-AGEsGlyceraldehyde-derived advanced glycation end-products
GC-MSGas chromatography-mass spectrometry
GLAPGlyceraldehyde-derived pyridinium
GOLDGlyoxal-lysine dimer
HPLCHigh performance liquid chromatography
HSPHeat shock protein
LSRDLifestyle-related disease
MAGEMelibiose-derived advanced glycation end-products
MALDI-MSMatrix assisted laser desorption-mass spectrometry
MG-H1Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine
MGO-AGEsMethylglyoxal-derived advanced glycation end-products
MOLDMethylglyoxal-lysine dimer
NASHNon-alcoholic steatohepatitis
NMRNuclear magnetic resonance
RAGEReceptor for advanced glycation end-products
SDS-PAGESodium dodecyl sulfate-polyacrylamide gel electrophoresis
TAGEToxic advanced glycation end-products
TLR4Tool like receptor 4

References

  1. Takata, T.; Motoo, Y. Novel In Vitro Assay of the Effects of Kampo Medicines against Intra/Extracellular Advanced Glycation End-Products in Oral, Esophageal, and Gastric Epithelial Cells. Metabolites 2023, 13, 878. [Google Scholar] [CrossRef] [PubMed]
  2. Takata, T.; Ueda, T.; Sakasa-Sakai, A.; Takeuchi, M. Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion. World J. Gastroenterol. 2017, 23, 4910–4919. [Google Scholar] [CrossRef] [PubMed]
  3. Manfredelli, D.; Pariano, M.; Costantini, C.; Graziani, A.; Bozza, S.; Romani, L.; Puccetti, P.; Talesa, V.N.; Antgonelli, C. Severe Acute Respiratory Syndrome Cornonavirus 2 (SARS-CoV-2) Spike Protein S1 Induces Methylglyoxa-Derived Hydroimidazolone/Receptor for Advanced Glycation End Products (MG-H1/RAGE) Activation to Promote Inflammation in Human Bronchial BEAS-2B Cells. Int. J. Mol. Sci. 2023, 24, 14868. [Google Scholar] [CrossRef] [PubMed]
  4. Bednarska, K.; Fecka, I.; Scheijen, J.L.M.; Ahles, S.; Vangrieken, P.; Schalkwijik, C.G. A Citrus and Pomegranate Complex Reduces Methylglyoxal in Healthy Elderly Subjects: Secondary Analysis of a Double-Blind Randomized Cross-Over Clinical Trial. Int. J. Mol. Sci. 2023, 24, 13168. [Google Scholar] [CrossRef] [PubMed]
  5. Takeuchi, M.; Sakasai-Sakai, A.; Takata, T.; Takaino, J.; Koriyama, Y. Effects of Toxic AGEs (TAGE) on Human Health. Cells 2022, 11, 2178. [Google Scholar] [CrossRef] [PubMed]
  6. Su, C.; Li, N.; Ren, R.; Wang, Y.; Su, X.; Lu, F.; Zhong, R.; Yang, L.; Ma, X. Progress in the Medical Value, Bioactive Copouneds, and Pharmacological Activities of Glynostemma pentaphyllum. Molecules 2021, 26, 6249. [Google Scholar] [CrossRef] [PubMed]
  7. Liu, P.; Zhao, H.; Luo, Y. Anti-Aging Implications of Astragalus membranaceus (Huangqui): A Well-Known Chinese Tonic. Aging Dis. 2017, 8, 868–886. [Google Scholar] [CrossRef]
  8. Li, L.; Zhang, Y.; Luo, Y.; Meng, X.; Pan, G.; Zhang, H.; Li, Y.; Zhang, B. The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications. Drug. Des. Devel. Ther. 2023, 17, 771–790. [Google Scholar] [CrossRef]
  9. Kuzan, A. Toxicity of advanced glycation end products (Review). Biochem. Rep. 2021, 14, 46. [Google Scholar] [CrossRef]
  10. Pinto, R.S.; Ferreira, G.S.; Silvestre, C.R.; de Fátima M Santana, M.; Nunes, V.S.; Ledesma, L.; Pinto, P.R.; de Assis, S.I.; Machado, U.F.; da Silva, E.S.; et al. Plasma advanced glycation end products and soluble receptor for advanced glycation end products as indicators of sterol content in human carotid atherosclerotic plaques. Diabetes Vasc. Dis. Res. 2022, 19, 14791641221085269. [Google Scholar] [CrossRef]
  11. Kehm, R.; Rückrimen, J.; Weber, D.; Deubel, S.; Grnue, T.; Höhn, A. Eddogenous advanced glycation end products in pancreatic islets after short-term carbohydrate intervention in obese, diabetes-prone mice. Nutr. Diabetes 2019, 9, 9. [Google Scholar] [CrossRef] [PubMed]
  12. LeWinter, M.M.; Taatjes, D.; Ashikaga, T.; Palmer, B.; Bishop, N.; VanBuren, P.; Bell, S.; Donaldson, C.; Meyer, M.; Margulies, K.B.; et al. Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. Physiol. Rep. 2017, 5, e13462. [Google Scholar] [CrossRef] [PubMed]
  13. Chang, G.; Yeh, Y.; Chen, W.; Ko, Y.; Pang, J.S.; Lee, H. Inhibition of Advanved Glycation End-Products Formation Attenuates Cardiac Electrical and Mechanical Remodeling and Vulnerability to Tachyarrthmias in Diabetic Rats. J. Pharmacol. Exp. Ther. 2019, 368, 66–78. [Google Scholar] [CrossRef] [PubMed]
  14. Takata, T.; Sakasai-Sakai, A.; Takeuchi, M. Intracellular Toxic Advanced Glycation End-Products in 1.4E7 Cell Line Induce Death with Reduction of Microtubule-Associated Protein 1 Light Chain 3 and p62. Nutrients 2022, 14, 332. [Google Scholar] [CrossRef]
  15. Takata, T.; Sakasa-Sakai, A.; Takeuchi, M. Intracellular Toxic Advanced Glycation End-Products May Induce Cell Death and Suppress Cardiac Fibroblasts. Metabolites 2022, 12, 615. [Google Scholar] [CrossRef] [PubMed]
  16. Taktata, T. Is the Novel Slot Blot a Useful Method for Quantification of Intracellular Advanced Glycation End-Products? Metabolites 2023, 13, 564. [Google Scholar] [CrossRef]
  17. Browicka-Szydełko, A.; Krzystek-Korpacka, M.; Kuzan, A.; Gostomaska-Pampuch, K.; Gacka, M.; Jakobsche-Policht, U.; Adamiec, R.; Gamian, A. Non-standard AGE4 epitopes that predict polyneuropathy independently of obesity can be detected by slot dot-blot immunoassay. Adv. Clin. Exp. Med. 2020, 29, 91–100. [Google Scholar] [CrossRef]
  18. Kashiwabara, S.; Hosoe, H.; Ohno, R.; Nagai, R.; Shiraki, M. Department and Evaluation of Novel ELISA for Determination of Urinary Pentosidine. J. Nutr. Sci. 2019, 65, 526–533. [Google Scholar] [CrossRef]
  19. Requena, J.R.; Ahmed, M.U.; Fountain, W.F.; Degenhardt, T.P.; Reddy, S.; Perez, C.; Lyons, T.J.; Jenkins, A.J.; Baynes, J.W.; Thorpe, S.R. Carboxymethylethanolamine, a Biomarker of Phospholipid Modification during the Maillard Reaction In Vivo. J. Biol. Chem. 1997, 272, 17473–17479. [Google Scholar] [CrossRef]
  20. Iles, R.K.; Iles, J.K.; Lacey, J.; Gardiner, A.; Zmuidinaite, R. Direct Detection of Glycated Human Serum Albumin and Hyperglycosylated IgG3 in Serum, by MALDI-ToF-Mass Spectrometry, as predictor of COVID-19 severity. Diagnosis 2022, 12, 2521. [Google Scholar] [CrossRef]
  21. Ohno, R.; Ichimaru, K.; Tanaka, S.; Sugawa, H.; Katsuta, N.; Sakake, S.; Tominaga, Y.; Ban, I.; Shirakawa, J.; Yamaguchi, Y.; et al. Glucoselysine is derived from fructose and accumulates in the eye lens of diabetic rats. J. Biol. Chem. 2019, 294, 17326–17338. [Google Scholar] [CrossRef] [PubMed]
  22. Bellier, J.; Nokin, M.; Karoyan, P.; Peulen, O.; Castronovo, V.; Bellachcèn, A. Methylglyoxal, a potent inducer of AGEs, connects between diabetes and cancer. Diabetes Res. Clin. Pract. 2019, 148, 200–211. [Google Scholar] [CrossRef] [PubMed]
  23. Matsui, T.; Joo, H.D.; Lee, J.M.; Ju, S.M.; Tao, W.H.; Higashimoto, Y.; Fukami, K.; Yamagishi, S. Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products. Immunol. Lett. 2015, 167, 141–146. [Google Scholar] [CrossRef] [PubMed]
  24. Jung, W.K.; Park, S.; Kim, H.R.; Ryu, H.Y.; Kim, Y.H.; Kim, J. Advanced Glycation End Products Increase Salivary Gland Hypofunction in D-Galactose-Induced Aging Rats and Its Prevention by Physical Exercise. Curr. Issues Mol. Biol. 2021, 43, 2059–2067. [Google Scholar] [CrossRef] [PubMed]
  25. Wada, K.; Nakahima, Y.; Yamakawa, M.; Hori, A.; Seishima, M.; Tanabashi, S.; Matsushita, S.; Tokimitsu, N.; Nagata, C. Dietary advanced glycation end-products and cancer risk in Japan: From the Takayama Study. Cancer Sci. 2022, 113, 2839–2848. [Google Scholar] [CrossRef]
  26. Hayashi, K.; Sato, K.; Ochi, S.; Kawano, S.; Munesue, S.; Harashima, A.; Oshima, Y.; Kimura, K.; Kyoi, T.; Yamamoto, Y. Inhibitory Effects of Saururus Chinensis Extract on Receptor for Advanced Glycation End-Products-Depenedent Inflammation and Diabetes-Induced Dysregulation of Vasodilation. Int. J. Mol. Sci. 2022, 23, 5757. [Google Scholar] [CrossRef]
  27. Cui, Q.; Du, H.; Ma, Y.; Wang, T.; Zhu, H.; Zhu, L.; Pan, S.; Min, N.; Wang, X.; Liu, Z. Matrine inhibits advanced glycation end products induced macrophage M1 polarization by reducing DNMT3a/b-mediated DNA methylation of GPX1 promoter. Eur. J. Pharmacol. 2022, 926, 175039. [Google Scholar] [CrossRef]
  28. Senavirathna, L.; Ma, C.; Chen, R.; Pan, S. Proteomic Investigation of Glyceraldehyde-Derived Intracellular AGEs and Their Potential Influence on Pancreatic Ductal Cells. Cells 2021, 10, 1005. [Google Scholar] [CrossRef]
  29. Nokin, M.; Durieux, F.; Peixoto, P.; Chiavarina, B.; Peulen, O.; Blomme, A.; Turtoi, A.; Costanza, B.; Smargiasso, N.; Baiwir, D. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife 2016, 19, e19375. [Google Scholar] [CrossRef]
  30. Kinoshita, S.; Mera, K.; Ichikawa, H.; Shimasaki, S.; Nagai, M.; Taga, Y.; Iijima, K.; Hattori, S.; Fujiwara, Y.; Shirakawa, J.; et al. Nω-(Carboxymethyl)arginine Is One of the Dominant Advanced Glycation End Products in Glycated Collagens and Mouse Tissues. Oxid. Med. Cell. Longev. 2019, 2019, 9073451. [Google Scholar] [CrossRef]
  31. Oya-Ito, T.; Naito, Y.; Takagi, T.; Handa, O.; Matsui, H.; Yamada, M.; Shima, K.; Yoshikawa, T. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochim. Biophys. Acta 2011, 1812, 769–781. [Google Scholar] [CrossRef] [PubMed]
  32. Mastrocola, R.; Collino, M.; Nigro, D.; Chiazza, F.; D’Antona, G.; Aragno, M.; Minetto, M. Accumulation of Advanced Glycation End-Products and Activation of the SCAP/SREBP Lipogenetic Pathway Occur in Diet-Induced Obese Mouse Skeletal Muscle. PLoS ONE 2015, 10, e0119587. [Google Scholar] [CrossRef] [PubMed]
  33. Chung, H.; Yuasa, M.; Chen, F.; Yukawa, K.; Motoo, Y.; Arai, I. The status of education for integrative medicines in Japanese medical universities with special reference to Kampo medicines. Traditi. Kampo Med. 2023, 10, 123–131. [Google Scholar] [CrossRef]
  34. Motoo, Y.; Seki, T.; Tsutani, K. Traditional Japanese medicine, Kampo: Its history and current status. Clin. J. Integr. Med. 2011, 17, 85–87. [Google Scholar] [CrossRef] [PubMed]
  35. Arai, I.; Kawabata, N. Kampo pharmaceutical products in the Japanese health-care system: Legal status and quality assurance. Trad. Kampo. Med. 2019, 6, 3–11. [Google Scholar] [CrossRef]
  36. Arai, I. Clinical studies of traditional Japanese herbal medicines (Kampo): Need for evidence by modern scientific methodology. Integr. Med. Res. 2021, 10, 100722. [Google Scholar] [CrossRef]
  37. Motoo, Y.; Hakamatsuka, T.; Kawahara, N.; Arai, I.; Tsutani, K. Standards of Reporting Kampo Products (STORK) in research articles. J. Integr. Med. 2017, 15, 182–185. [Google Scholar] [CrossRef]
  38. Motoo, Y.; Arai, I.; Tsutani, K. Use of Kampo Diagnosis in Randomized Controlled Trials of Kampo Products in Japan: A Systematic Review. PLoS ONE 2014, 9, e104422. [Google Scholar] [CrossRef]
  39. Motoo, Y.; Arai, I.; Kogure, T.; Tsutani, K. Review of the first 20 years Evidence-Based Medicine Committee of the Japan Society for Oriental Medicine. Trad. Kampo Med. 2021, 8, 123–139. [Google Scholar] [CrossRef]
  40. Motoo, Y. Role of Kampo Medicine in Modern Cancer Therapy: Towards Completion of Standard Treatment. J. Nippon. Med. Sch. 2022, 89, 139–144. [Google Scholar] [CrossRef]
  41. Motoo, Y.; Cameron, S. Kampo medicines for supportive care of patients with cancer: A brief review. Integr. Med. Res. 2022, 11, 100839. [Google Scholar] [CrossRef] [PubMed]
  42. Suzuki, T.; Yamamoto, A.; Ohsawa, M.; Motoo, Y.; Mizukami, H.; Makino, T. Effect of ninjin’yoeito and ginseng extracts on oxliplation-induced neuropathies in micie. J. Nat. Med. 2017, 71, 757–764. [Google Scholar] [CrossRef] [PubMed]
  43. Sameshima-Uto, N.; Amitani, H.; Atobe, Y.; Sameshima, Y.; Sakaki, M.; Rokot, N.; Ataka, K.; Amitani, M.; Inui, A. Herbal Medicine Ninjin’yoeito in the Treatment of Sarcopenia and Frailty. Front. Nutr. 2018, 5, 126. [Google Scholar]
  44. Ohnishi, Y.; Fujii, H.; Hayakawa, Y.; Sakukawa, R.; Yamamura, T.; Sakamoto, T.; Tsukada, K.; Fujimaki, M.; Nunome, S.; Komatsu, Y.; et al. Oral Administration of Kampo (Japanese Herbal) Medicine Juzen-taiho-to Inhibits Liver Metastastics of Colon 26-L5 Carcinoma Cells. Jpn. J. Cancer. Res. 1998, 89, 206–213. [Google Scholar] [CrossRef] [PubMed]
  45. Takagi, K.; Sugihira, T.; Kitamura, M.; Kawai, M.; Mitsuguchi, Y.; Tsukamoto, K.; Nakanishi, H.; Makino, T. Inhibitory effect of Bofutushosan (Fangfengtongshengsan) extract on the absorption of fructose in rats and mice. J. Nat. Med. 2023, 77, 533–543. [Google Scholar] [CrossRef] [PubMed]
  46. van Heijist, J.W.J.; Niessen, H.W.M.; Musters, R.J.; van Hinsbergh, V.W.M.; Hoekuman, K.; Schalkwijk, C.G. Argpyrimidine-modified Heat Shock Protein 27 in human non-small cell lung cancer: A possible mechanism for evasion of apoptosis. Cancer Lett. 2006, 241, 309–319. [Google Scholar] [CrossRef] [PubMed]
  47. Suh, K.; Choi, E.; Jung, W.; Kim, Y.J.; Hong, S.M.; Park, S.Y.; Rhee, S.Y.; Chon, S. Deoxyactein protects pancreatic β-cells against methylglyoxal-induced oxidative cell damage by the upregulation of mitochondrial biogenesis. Int. J. Mol. Med. 2017, 40, 539–548. [Google Scholar] [CrossRef]
  48. Ikeda, K.; Higashi, T.; Sano, H.; Jinnouchi, Y.; Yoshida, M.; Araki, T.; Ueda, S.; Horiuchi, S. N (epsilon)–(carboxymethyl)lysine protein adducts is a major immunoglogical epitope in proteins modified with advanced glycation end products of Maillard reaction. Biochemistry 1996, 35, 8075–8083. [Google Scholar] [CrossRef]
  49. Ikeda, K.; Nagai, R.; Sakamoto, T.; Sano, H.; Araki, T.; Sakata, N.; Nakayama, H.; Yoshida, M.; Ueda, S.; Horiuchi, S. Imunochemical approaches to AGE–structures: Characterization of anti-AGE antibodies. J. Immunol. Methods 1998, 215, 95–104. [Google Scholar] [CrossRef]
  50. Sakasai-Sakai, A.; Takata, T.; Suzuki, H.; Maruyama, I.; Motomiya, Y.; Takeuchi, M. Immunological evidence for in vivo production of novel advanced glycation end-products from 1,5-anhydro-D-fructose, a glycogen metabolite. Sci. Rep. 2019, 9, 10194. [Google Scholar] [CrossRef]
  51. Papadaki, M.; Holewinski, R.J.; Previs, S.B.; Martin, T.G.; Stachowski, M.J.; Li, A.; Blair, C.A.; Morave, C.S.; Van Eyk, J.E.; Campbell, K.S.; et al. Diabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function. JCI Insight 2018, 3, e121264. [Google Scholar] [CrossRef] [PubMed]
  52. Ruiz-Meana, M.; Minguet, M.; Bou-Teen, D.; Miro-Casas, E.; Castans, C.; Castellano, J.; Bonzon-Kulichenko, E.; Igual, A.; Rodriguez-Lecoq, R.; Vázquez, J.; et al. Ryanodine Receptor Glycation Favors Mitochondrial Damage in the Senescent Heart. Circulation 2019, 139, 949–964. [Google Scholar] [CrossRef] [PubMed]
  53. Baskal, S.; Bollenbach, A.; Mels, C.; Kruger, R.; Tskas, D. Development, validation of a GC-MS method for the simultaneous measurement of amino acids, their PTM metabolites and AGEs in human urine, and application to the bi-ethnic ASOS study with special emphasis to lysine. Amino Acids 2022, 54, 615–641. [Google Scholar] [CrossRef] [PubMed]
  54. Baskal, S.; Büttner, P.; Werner, S.; Besler, C.; Lurz, P.; Thiele, H.; Tsikas, D. Profile of urinary amino acids and their post-translational modifications (PTM) including advanced glycation end-products (AGE) of lysine, arginine and cysteine in lean and obese ZSF1 rats. Amino Acids 2022, 54, 643–652. [Google Scholar] [CrossRef] [PubMed]
  55. Baskal, S.; Tsikas, D. Free L-Lysine and Its Methyl Ester React with Glyoxal and Methylglyoxyal in Phosphate Buffer (100 mM, pH 7.4) to Form Nε-Carboxymethel-Lysine, Nε-Carboxytheyl-Lysine and Nε-Hydroxymethyl-Lysine. Int. J. Mol. Sci. 2022, 23, 3446. [Google Scholar] [CrossRef]
  56. Baskal, S.; Kaiser, A.; Mels, C.; Kruger, R.; Tsikas, D. Specific and sensitive GC-MS analysis of hypusine, Nε-(4-amino-2-hydoroxybutyle)lysine, a biomarker of hypusinated eukaryotic initiation factor elF5A, and its application to the bi-ethnic ASOS study. Amino Acids 2022, 54, 1083–1099. [Google Scholar] [CrossRef]
  57. Shorey-Kendrick, L.E.; Crosland, B.A.; Spindel, E.R.; McEvoy, C.T.; Wilmarth, P.A.; Reddy, A.P.; Zientek, K.D.; Roberts, V.H.J.; D’Mello, R.J.; Ryan, K.S.; et al. The amniotic fluid proteome changes across gestation in human and rhesus macaques. Sci. Rep. 2023, 13, 17039. [Google Scholar] [CrossRef]
  58. Ge, S.; Lian, W.; Bai, Y.; Wang, L.; Zho, F.; Li, H.; Wang, D.; Pang, Q. TMT-based quantitative proteomics reveals the targets of andrographolide on LPS-induced liver injury. BMC Vet. Res. 2023, 19, 199. [Google Scholar] [CrossRef]
  59. Takata, T.; Ishigaki, Y.; Shimasaki, T.; Tsuchida, H.; Motoo, Y.; Hayashi, A.; Tomosugi, N. Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Oncol. Rep. 2012, 28, 1968–1976. [Google Scholar] [CrossRef]
  60. Niwa, T. Mass Spectrometry for Study of Protein Glycation in Disease. Mass Spectrom. Rev. 2006, 25, 713–723. [Google Scholar] [CrossRef]
  61. Krause, R.; Kühn, J.; Knoll, P.K.; Henle, T. N-Terminal pyrazinones: A new class of peptide-bound advanced glycation end-products. Amino Acids 2004, 27, 9–18. [Google Scholar] [CrossRef] [PubMed]
  62. Fujimoto, S.; Murakami, Y.; Miyake, H.; Hayase, F.; Watanabe, H. Identification of a novel advanced glycation end product derived from lactaldehyde. Biosci. Biotechnol. Biochem. 2019, 83, 1136–1145. [Google Scholar] [CrossRef] [PubMed]
  63. Cai, J.; Hurst, H.E. Identification and Quantitation of N-(Carboxymethyl)valine Adduct in Hemoglobin by Gas Chromatography/Mass Spectrometry. J. Mass Spectrom. 1999, 34, 537. [Google Scholar] [CrossRef]
  64. Katsuta, N.; Takahashi, H.; Nagai, M.; Sugawa, H.; Nagai, R. Changes in S-(2-succinyl)cysteine and advanced glycation end-products levels in mouse tissues associated with aging. Amino Acids 2022, 54, 653–661. [Google Scholar] [CrossRef]
  65. Mastrocola, R.; Nigro, D.; Chiazza, F.; Medana, C.; Dal Bello, F.; Boccuzzi, G.; Collino, M.; Aragno, M. Fructose-derived advanced glycation end-products drive lipogenesis and skeletal muscle reprograming via SREBP-1c dysregulation in mice. Free Radic. Biol. Med. 2016, 91, 224–235. [Google Scholar] [CrossRef]
  66. Lapolla, A.; Fedele, D.; Seraglia, R.; Traldi, P. The Role of Mass Spectrometry in the Study of Non-Enzymatic Protein Glycation in Diabetes: An update. Mass Spectrom. Rev. 2006, 25, 775–797. [Google Scholar] [CrossRef] [PubMed]
  67. Perween, S.; Abidi, M.; Faizy, A.F.; Moinuddin. Post-translational modifications on glycated plasma fibrinogen: A physicochemical insight. Int. J. Biol. Macromol. 2019, 126, 1201–1212. [Google Scholar] [CrossRef]
  68. Ghosh, P.; Kishore, N. Mechanistic physicochemical insights into glycation and drug binding by serum albumin: Implications in diabetic conditions. Biochimie 2022, 193, 16–37. [Google Scholar] [CrossRef]
  69. Kuang, L.; Jing, Z.; Wang, J.; Ma, L.; Liu, X.; Yang, J. Quantitative determination of ε-N-Carboxymethyl-L-lysine in human plasma by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2014, 90, 1–6. [Google Scholar] [CrossRef]
  70. Kato, S.; Sugawa, H.; Tabe, K.; Ito, K.; Nakashima, H.; Nagai, R. Rapid pretreatment for multi-sample analysis of advanced glycation end products and their role in nephropathy. J. Clin. Biochem. Nutr. 2022, 70, 256–261. [Google Scholar] [CrossRef]
  71. Litwinowicz, K.; Waszczuk, E.; Kuzan, A.; Bronowicka-Szydełko, A.; Gostomaska-Pampuch, K.; Naporowaski, P.; Gamian, A. Alcoholic Liver Disease Is Associated with Elevated Plasma Levels of Novel Advanced Glycation End-Products; A Preliminary Study. Nutrients 2022, 14, 5266. [Google Scholar] [CrossRef] [PubMed]
  72. Cao, R.; Cao, C.; Hu, X.; Du, K.; Zhang, J.; Li, M.; Li, B.; Lin, H.; Zhang, A.; Li, Y.; et al. Kaempferol attenuates carbon tetrachloride (CCl4)-induced hepatic fibrosis by promoting ASIC1a degradation and suppression of the ASIC1a-mediated ERS. Phytomedicine 2023, 121, 155125. [Google Scholar] [CrossRef] [PubMed]
  73. Xu, L.L.; Long, C.Y.; Wang, J.L.; Yu, M.; Chen, J.X. Involvement of oxidative stress in tri-ortho-cresyl phosphate-induced liver injury in male mice. Hum. Exp. Toxicol. 2016, 35, 1093–1101. [Google Scholar] [CrossRef] [PubMed]
  74. Tabansi, D.; Dahiru, D.; Patric, A.T.; Jahng, W.J. Anti-Atherosclerosis and Anti-Hyperlipidemia Functions of Terminalia catappa Fruit. ACS Omega. 2023, 39, 35571–35579. [Google Scholar] [CrossRef]
  75. Liu, Y.; Xie, C.; Hou, Y.; Li, K.; Wang, Q.; Lin, L.; Tang, M.; Yang, P.; Wu, J. The effects of prophylactic intravenous injection of rhBNP on prognosis in patients with STEMI undergoing PPCI. Cell Mol. Biol. 2023, 69, 156–160. [Google Scholar]
  76. Chen, J.; Radijiazadeh, D.; Medina-Gomez, C.; Voortman, T.; van Merus, J.B.; Ikram, M.A.; Uitterlinden, A.G.; Kraaij, R.; Zillikens, C. Advanced Glycation End Products (AGEs) in Diet and Skin in Relation to Stool Microbaita: The Rotterdam Study. Nutrients 2023, 15, 2567. [Google Scholar] [CrossRef]
  77. Phung-Nguyen, K.; McNeill, B.A.; Aston-Mourney, K.; Rivera, L.R. Advanced Glycation End-Products and Their Effects on Gut Health. Nutrients 2023, 15, 405. [Google Scholar] [CrossRef]
  78. Oh, S.; Yang, J.; Park, C.; Son, K.; Byun, K. Dieckol Attenuated Glucocorticoid-Induced Muscle Atrophy by Decreasing NLR3 Inflammasome and Pyroptosis. Int. J. Mol. Sci. 2021, 22, 8057. [Google Scholar] [CrossRef]
  79. Tancharoen, S.; Gando, S.; Binita, S.; Nagasato, T.; Kikuchi, K.; Nawa, Y.; Dararat, P.; Yamamoto, M.; Narkpinit, S.; Maruyama, I. HMGB-1 Promotes Intraoral Palatal Wound Healing trhough RAGE-Dependent Mechanisms. Int. J. Mol. Sci. 2016, 17, 1961. [Google Scholar] [CrossRef]
  80. Kido, R.; Hiroshima, Y.; Kido, J.; Ikuta, T.; Sakamoto, E.; Inagaki, Y.; Naruishi, K.; Yumoto, H. Advanced glycation end-products lipocalin 2 expression in human oral epithelial cells. J. Periodontal. Res. 2020, 55, 539–550. [Google Scholar] [CrossRef]
  81. Ji, M.; Sun, J.; Zhao, J. Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42/via the HMGB1/RAGE axis. Hum. Exp. Toxicol. 2020, 41, 96032712217429. [Google Scholar] [CrossRef]
  82. Rojas, A.; Linder, C.; Schneider, I.; González, I.; Morales, M.A. Contributions of the receptor for advanced glycation end products axis activation gastric cancer. World J. Gastroenterol. 2023, 29, 997–1010. [Google Scholar] [CrossRef]
  83. Lin, Y.; Zhang, W.; Liu, L.; Li, W.; Li, B. ENO1 Promotes OSCC Migration and Investigation by Orchestrating IL-6 Secretion from Macrophages via a Positive Feedback Loop. Int. J. Mol. Sci. 2023, 24, 737. [Google Scholar] [CrossRef]
  84. Nadatani, Y.; Huo, X.; Zhang, X.; Yu, C.; Cheng, E.; Zhang, Q.; Dunbar, K.B.; Theiss, A.; Pharm, T.H.; Wang, D.H.; et al. NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett’s Epithelial Cells. Cell. Mol. Gastroenterol. Hepatol. 2016, 2, 439–453. [Google Scholar] [CrossRef]
  85. Chen, Y.; Huang, J.; Xu, C. Lipopolysaccharide-induced DC-SIGN/TLR4 crosstalk activates NLRP3 inflammasomes via My88-independent signaling in gastric epithelial cells. Exp. Cell Res. 2020, 396, 112292. [Google Scholar] [CrossRef]
  86. Leone, A.; Nigro, C.; Nicolò, A.; Prevenzano, I.; Formisano, P.; Beguínot, F.; Miele, C. The Dual-Role of Methylglyoxal in Tumor Progression–Novel Terapeutic Approaches. Front. Oncol. 2021, 11, 64586. [Google Scholar] [CrossRef]
  87. Usui, T.; Hayase, F. Isolation and Identification of the 3-Hydroxy-5-hydroxymethyl-pyridinium Compounds as a Novel Advanced Glycation End Products on Glyceraldehyde-related Maillard Reaction. Biosci. Biotechnol. Biochem. 2003, 67, 930–932. [Google Scholar] [CrossRef]
  88. Usui, T.; Shimohira, K.; Watanabe, H.; Hayase, F. Detection and Determination of Glyceraldehyde-Derived Pyridinium-Type Advanced Glycation End Products in Streptozotocin Diabetic Rats. Biosci. Biotechnol. Biochem. 2007, 71, 442–448. [Google Scholar] [CrossRef]
  89. Usui, T.; Shizuuchi, S.; Watanabe, H.; Hayase, F. Cytotoxicity and Oxidative Induced by the Glyceraldehyde-related Maillard Reaction Products for HL-60 Cells. Biosci. Biotechnol. Biochem. 2004, 68, 333–340. [Google Scholar] [CrossRef]
  90. Tessier, F.J.; Monnier, V.M.; Sayre, L.M.; Kornfield, J.A. Triosidines: Novel Maillard reaction products and cross-links from the reaction of triose sugars with lysine and arginine residues. Biochem. J. 2003, 369, 705–719. [Google Scholar] [CrossRef]
  91. Usui, T.; Watanabe, H.; Hayase, F. Isolation and Identification of 5-Methyl-imidazolin-4-one Derivative as Glyceraldehyde-Derived Advanced Glycation End Product. Biosci. Biotechnol. Biochem. 2006, 70, 1496–1498. [Google Scholar] [CrossRef]
  92. Usui, T.; Ohguchi, M.; Watanabe, H.; Hayase, F. The Formation of Argpyrimidine in Glyceraldehyde-Related Glycation. Biosci. Biotechnol. Biochem. 2008, 72, 568–571. [Google Scholar] [CrossRef]
  93. Ahmed, N.; Thornalley, P.J. Peptide Mapping of Human Serum Albumin Modified Minimally by Methylglyoxal In Vitro and In Vivo. Ann. N. Y. Acad. Sci. 2005, 1043, 260–266. [Google Scholar] [CrossRef]
  94. Hayase, F.; Usui, T.; Nishiyama, K.; Sasaki, S.; Shirahashi, Y.; Tsuchiya, N.; Numata, N.; Watanabe, H. Chemistry and Biological Effects of Melanoidins and Glyceraldehyde-Derived Pyridinium as Advanced Glycation End Products. Ann. N. Y. Acad. Sci. 2005, 1043, 104–110. [Google Scholar] [CrossRef]
  95. Sakamoto, H.; Mashima, T.; Yamamoto, K.; Tsuruo, T. Modulation of Heat-shock Protein 27 (Hsp27) Anti-apoptotic Activity by Methylglyoxal Modification. J. Biol. Chem. 2002, 277, 45770–45775. [Google Scholar] [CrossRef]
  96. Best, L.; Thornalley, P.J. Trioses and Related Substances: Tools for the Study of Pancreatic β-Cell Function. Biochem. Pharamcol. 1999, 57, 583–588. [Google Scholar]
  97. Wang, X.; Lau, W.; Yuan, Y.; Wang, Y.; Yi, W.; Chritopher, T.A.; Lopez, B.L.; Liu, H.; Ma, X. Methylglyoxal increases cardiomyocyte ischemia-reprefusion injury via glycative inhibition of thioredoxin activity. Am. J. Physiol. Endocrinol. 2010, 299, E207–E214. [Google Scholar] [CrossRef]
  98. Kishida, Y.; Kagawa, S.; Arimitsu, J.; Nakanishi, M.; Sakashita, N.; Otsuka, S.; Yoshikawa, H.; Hagihara, K. Go-sha-jinki-Gan (GJG), a traditional Japanese herbal medicine, protects against in senescence-accelarated mice. Phytomedicine 2015, 22, 16–22. [Google Scholar] [CrossRef]
  99. Nakanishi, M.; Nake, A.; Kishida, Y.; Baba, K.; Sakashita, N.; Shibata, M.; Yoshikawa, H.; Hagihara, K. Go-sha-jinki-Gan (GJG) ameliorates allodynia in chronic constriction injury model mice via suppression of TNF-α expression in the spinal cord. Mol. Pain. 2016, 12, 1744806916656382. [Google Scholar] [CrossRef]
  100. Hosogi, S.; Ohsawa, M.; Kato, I.; Kuwahara, A.; Inui, T.; Marunaka, Y. Improvement of Diabetes Mellitus Symptoms by Intake of Ninjin’yoeito. Front. Nutr. 2018, 5, 112. [Google Scholar] [CrossRef]
  101. Hu, Z.; Liu, X.; Yang, M. Evidence and Potential Mechanisms of Ji-Gui Shen-Qi-Wan as a Treatmetnt for Type 2 Diabetes Mellitus: A systematic Review and Meta-Analysis. Front. Pharmacol. 2021, 12, 699932. [Google Scholar] [CrossRef]
  102. Sun, G.; Li, C.; Cui, W.; Guo, Q.; Dong, C.; Zou, H.; Liu, S.; Dong, W.; Miao, L. Review of Herbal Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy. J. Diabetes Res. 2016, 2016, 5749857. [Google Scholar] [CrossRef]
  103. Fujimoto, M.; Tsuneyama, K.; Kinoshita, H.; Goto, H.; Takano, T.; Simi, G.; Keen, C.L.; Gershwin, M.E.; Shimada, Y. The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalchoholic fatty liver disease. Ann. N. Y. Acad. Sci. 2010, 1190, 151–158. [Google Scholar] [CrossRef]
  104. Han, K.; Kwon, O.; Park, H.; Jung, S.; Yang, C.; Son, C. Effect of Daeshio-tang on obesity with non-alcoholic fatty liver disease: A study protocol for a randomized, double-blind, placebo-controlled pilot traial. Traials 2020, 21, 128. [Google Scholar] [CrossRef]
  105. Yamakawa, J.; Moriya, J.; Takeuchi, K.; Nakatou, M.; Motoo, Y.; Kobayashi, J. Significance of Kampo, Japanese Traditional Medicine, in the Treatment of Obesity: Basic and Clinical Evidence. Evid.-Based Complement. Altern. Med. 2013, 2013, 943075. [Google Scholar] [CrossRef]
  106. Uneda, K.; Kawai, Y.; Yamada, T.; Kaneko, A.; Saito, R.; Chen, L.; Ishigami, T.; Namiki, T.; Mitsuma, T. Japanese traditional Kampo medicine bofutsushosan improves body mass index in participants with obesity: A systematic review and meta-analysis. PLoS ONE 2022, 17, e0266917. [Google Scholar] [CrossRef]
  107. Suzuki, H.; Kaneko, T.; Mizokami, Y.; Narasaki, T.; Endo, S.; Matsui, H.; Yanaka, A.; Hirayama, S.; Hyodo, I. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World. J. Gastroenterol. 2013, 19, 2718–2722. [Google Scholar] [CrossRef]
  108. Kubota, K.; Imai, Y.; Okuyama, T.; Ishiyama, Y.; Ueno, S.; Kario, K. Dramatically Improved Severe Pulmonary Arterial Hypertension Caused by Qing-Dai (Chinese Herbal Drug) for Ulcerative Colitis. Int. Heart J. 2023, 64, 316–320. [Google Scholar] [CrossRef]
  109. Añazco, C.; Riedelsberger, J.; Vega-Montoto, L.; Rojas, A. Exploring the Interplay between Polyphenols and Lysyl Oxidase Enzymes for Maintaining Extracellular Matrix Homeostasis. Int. J. Mol. Sci. 2023, 13, 10985. [Google Scholar] [CrossRef]
  110. Yadv, N.; Palkhede, J.D.; Kim, S. Anti-Glucotoxicity Effect of Phytoconstituents Via Inhibiting MGO-AGEs Formation and Breaking MGO-AGEs. Int. J. Mol. Sci. 2023, 24, 7672. [Google Scholar] [CrossRef] [PubMed]
  111. Zhi, J.; Yin, L.; Zhang, Z.; Lv, Y.; Wu, F.; Yang, Y.; Zhang, E.; Li, H.; Zhou, M.; Hu, Q. Network pharmacology–based analysis of Jin-Si-Wei on the treatment of Alzheimer’s disease. J. Ethnopharmacol. 2024, 319, 117291. [Google Scholar] [CrossRef]
  112. Liu, Z.; Zheng, Z.; Wang, T.; Liu, Z.; Zuo, Z. Using ultra-performance liquid chromatography with linear ion trap–electrostatic field orbitrap mass spectrometry, network pharmacology, and molecular docking to explore the constituent targets and action mechanisms of decoction of Angelica Sinensis, Zingiberis Rhizoma Recens, and Mutton in the treatment of diarrhea–predominant irritable bowel syndrome. J. Pharm. Pharmacol. 2023. online ahead of print. [Google Scholar]
  113. Ban, I.; Sugawa, H.; Nagai, R. Protein Modification with Ribose Generates Nδ-(5-hydro-5-methyl-1,4-imidazolone-2-yl)-ornithine. Int. J. Mol. Sci. 2022, 23, 1224. [Google Scholar] [CrossRef]
  114. Tominaga, Y.; Sugawa, H.; Hirabayashi, K.; Ikeda, T.; Hoshi, Y.; Nagai, R. Drosera tokainesis extract containing multiple phenolic compounds inhibits the formation of advanced glycation end-products. Arch. Biochem. Biophys. 2020, 693, 108586. [Google Scholar] [CrossRef]
  115. Takata, T.; Masauji, T.; Motoo, Y. Potential of the Novel Slot Blot Method with a PVDF Membrane for Protein Identification and Quantification in Kampo Medicines. Membranes 2023, 13, 896. [Google Scholar] [CrossRef]
Metabolites 14 00003 g001
Figure 1. Model image of the preparation of a CEL-ester derivative for GC-MS analysis. Closed blue circles represent amino acids. Closed peach squares represent compounds that have hydroxyl groups. CEL: Nε-carboxyethyl-lysine.
Figure 1. Model image of the preparation of a CEL-ester derivative for GC-MS analysis. Closed blue circles represent amino acids. Closed peach squares represent compounds that have hydroxyl groups. CEL: Nε-carboxyethyl-lysine.
Metabolites 14 00003 g001
Metabolites 14 00003 g002
Figure 2. Hydrochloride hydrolysis of various CEL-modified proteins and production of free CEL for analysis using MALDI-MS or ESI-MS. CEL: Nε-carboxyethyl-lysine; MALDI-MS, matrix-assisted laser desorption-mass spectrometry; ESI-MS, electrospray ionization-mass spectrometry.
Figure 2. Hydrochloride hydrolysis of various CEL-modified proteins and production of free CEL for analysis using MALDI-MS or ESI-MS. CEL: Nε-carboxyethyl-lysine; MALDI-MS, matrix-assisted laser desorption-mass spectrometry; ESI-MS, electrospray ionization-mass spectrometry.
Metabolites 14 00003 g002
Metabolites 14 00003 g003
Figure 3. Model image of MALDI-MS or ESI-MS analysis of GLAP-modified protein. GLAP, glyceraldehyde-derived pyridinium; MALDI-MS, matrix-assisted laser desorption-mass spectrometry; ESI-MS, electrospray ionization-mass spectrometry.
Figure 3. Model image of MALDI-MS or ESI-MS analysis of GLAP-modified protein. GLAP, glyceraldehyde-derived pyridinium; MALDI-MS, matrix-assisted laser desorption-mass spectrometry; ESI-MS, electrospray ionization-mass spectrometry.
Metabolites 14 00003 g003
Metabolites 14 00003 g004
Figure 4. New model of categorizing MGO-AGEs and GA-AGEs. Numbers indicate references. MGO-AGEs, methylglyoxal-derived AGEs; GA-AGEs, glyceraldehyde-derived AGEs; CML, Nε-carboxymethyl-lysine [55,97]; CEL, Nε-carboxyethyl-lysine [55,96]; MOLD, methylglyoxal-lysine dimer (1,3-di(Nε-lysino)-4-methyl-imidazolium salt) [5,60]; MG-H1, Nε-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine [91,93,94]; Argpyrimidine [92,95,96]; GLAP, glyceraldehyde-derived pyridinium [87,88,89]; TAGE, toxic AGEs [2,5]; Triosidines [90].
Figure 4. New model of categorizing MGO-AGEs and GA-AGEs. Numbers indicate references. MGO-AGEs, methylglyoxal-derived AGEs; GA-AGEs, glyceraldehyde-derived AGEs; CML, Nε-carboxymethyl-lysine [55,97]; CEL, Nε-carboxyethyl-lysine [55,96]; MOLD, methylglyoxal-lysine dimer (1,3-di(Nε-lysino)-4-methyl-imidazolium salt) [5,60]; MG-H1, Nε-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine [91,93,94]; Argpyrimidine [92,95,96]; GLAP, glyceraldehyde-derived pyridinium [87,88,89]; TAGE, toxic AGEs [2,5]; Triosidines [90].
Metabolites 14 00003 g004
Metabolites 14 00003 g005
Figure 5. Illustration of the generation and accumulation of various AGEs in PANC-1 cells treated with glyceraldehyde [28] via the crude AGE pattern. GA, glyceraldehyde; Arg-P, argpyrimidine; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine. GLAP, glyceraldehyde-derived pyridinium; AGEs, advanced glycation end-products.
Figure 5. Illustration of the generation and accumulation of various AGEs in PANC-1 cells treated with glyceraldehyde [28] via the crude AGE pattern. GA, glyceraldehyde; Arg-P, argpyrimidine; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine. GLAP, glyceraldehyde-derived pyridinium; AGEs, advanced glycation end-products.
Metabolites 14 00003 g005
Metabolites 14 00003 g006
Figure 6. Type 1 diverse AGE pattern. Each protein A can be modified by MG-H1, Arg-P, and CEL. Blue closed circles indicate the amino acids. MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; Arg-P: argpyrimidine; CEL, Nε-carboxyethyl-lysine.
Figure 6. Type 1 diverse AGE pattern. Each protein A can be modified by MG-H1, Arg-P, and CEL. Blue closed circles indicate the amino acids. MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; Arg-P: argpyrimidine; CEL, Nε-carboxyethyl-lysine.
Metabolites 14 00003 g006
Metabolites 14 00003 g007
Figure 7. MG-H1 and argypyrimidine-modified peptides in HSP27 [31]. Closed blue circles represent amino acids. Numbers indicate amino acids in the HSP27 sequence. MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; Arg-P: argpyrimidine; (a) The amino acid sequence: HGYISRCFTR (131–140). (b) Amino acid sequence: SRAQJGGPEAAR (187–198).
Figure 7. MG-H1 and argypyrimidine-modified peptides in HSP27 [31]. Closed blue circles represent amino acids. Numbers indicate amino acids in the HSP27 sequence. MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; Arg-P: argpyrimidine; (a) The amino acid sequence: HGYISRCFTR (131–140). (b) Amino acid sequence: SRAQJGGPEAAR (187–198).
Metabolites 14 00003 g007
Metabolites 14 00003 g008
Figure 8. Type 2 diverse AGE pattern. CEL-modified proteins A–C [32]. Closed blue circles represent amino acids. CEL, Nε-carboxyethyl-lysine.
Figure 8. Type 2 diverse AGE pattern. CEL-modified proteins A–C [32]. Closed blue circles represent amino acids. CEL, Nε-carboxyethyl-lysine.
Metabolites 14 00003 g008
Metabolites 14 00003 g009
Figure 9. Model of the type I multiple AGE pattern and the MALDI-MS or ESI-MS analysis of Arg-P-, MG-H1-, and CEL-modified proteins. The peptide modified with two MG-H1s verified the type I multiple AGE pattern. Closed blue circles represent amino acids. Arg-P: argpyrimidine; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; CEL, Nε-carboxyethyl-lysine.
Figure 9. Model of the type I multiple AGE pattern and the MALDI-MS or ESI-MS analysis of Arg-P-, MG-H1-, and CEL-modified proteins. The peptide modified with two MG-H1s verified the type I multiple AGE pattern. Closed blue circles represent amino acids. Arg-P: argpyrimidine; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; CEL, Nε-carboxyethyl-lysine.
Metabolites 14 00003 g009
Metabolites 14 00003 g010
Figure 10. Two MG-H1-modified peptides (65–87 and 88–96) in recombinant human HSP27 [31]. Closed blue circles represent amino acids. Numbers indicate amino acids in the HSP27 sequence. MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine. (a) The amino acid sequence: SPAVAAPAYSRALSRQJSSGVSE (65–87). (b) The amino acid sequence: IRHTADRWR (88–96).
Figure 10. Two MG-H1-modified peptides (65–87 and 88–96) in recombinant human HSP27 [31]. Closed blue circles represent amino acids. Numbers indicate amino acids in the HSP27 sequence. MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine. (a) The amino acid sequence: SPAVAAPAYSRALSRQJSSGVSE (65–87). (b) The amino acid sequence: IRHTADRWR (88–96).
Metabolites 14 00003 g010
Metabolites 14 00003 g011
Figure 11. Model image of the type II multiple AGE pattern shows only an intermolecular covalent bond. D1: AGE structure that can combine between the second amino acid residue in protein A and the third amino acid residue in protein B. Closed blue circles represent amino acids; black and red numbers represent the number of amino acid residues in proteins A and B, respectively.
Figure 11. Model image of the type II multiple AGE pattern shows only an intermolecular covalent bond. D1: AGE structure that can combine between the second amino acid residue in protein A and the third amino acid residue in protein B. Closed blue circles represent amino acids; black and red numbers represent the number of amino acid residues in proteins A and B, respectively.
Metabolites 14 00003 g011
Metabolites 14 00003 g012
Figure 12. Model image of the type II multiple AGE pattern shows both inter- and intramolecular covalent bonds. D1: AGE structure combining the second amino acid residue in protein A and the third amino acid residue in protein B. D2: AGE structure combining the fourth and thirteenth amino acids in protein A. D1 and D2 are different AGE structures. A closed black plow represents an anti-D2-antibody. Closed blue circles represent amino acids; black and red numbers represent the number of amino acid residues in proteins A and B, respectively.
Figure 12. Model image of the type II multiple AGE pattern shows both inter- and intramolecular covalent bonds. D1: AGE structure combining the second amino acid residue in protein A and the third amino acid residue in protein B. D2: AGE structure combining the fourth and thirteenth amino acids in protein A. D1 and D2 are different AGE structures. A closed black plow represents an anti-D2-antibody. Closed blue circles represent amino acids; black and red numbers represent the number of amino acid residues in proteins A and B, respectively.
Metabolites 14 00003 g012
Metabolites 14 00003 g013
Figure 13. MALDI-MS or ESI-MS analysis of the protein A and B complex, combined via D1. D1: AGE structure that can combine the second amino acid residue in protein A and the third amino acid residue in protein B. Closed blue circles indicate amino acids. Black and red numbers represent the number of amino acid residues in proteins A and B, respectively.
Figure 13. MALDI-MS or ESI-MS analysis of the protein A and B complex, combined via D1. D1: AGE structure that can combine the second amino acid residue in protein A and the third amino acid residue in protein B. Closed blue circles indicate amino acids. Black and red numbers represent the number of amino acid residues in proteins A and B, respectively.
Metabolites 14 00003 g013
Metabolites 14 00003 g014
Figure 14. Modern Kampo medicines from Tsumura Co. (Tokyo, Japan) (a) Tokishakuyakusan (2.5 g) packaged for use in hospitals or pharmacies. (b) Tokishakuyakusan (2.5 g). (c) Orento in a bottle, prepared for research at Kanazawa Medical University but not for use in hospitals or pharmacies. (d) Orento.
Figure 14. Modern Kampo medicines from Tsumura Co. (Tokyo, Japan) (a) Tokishakuyakusan (2.5 g) packaged for use in hospitals or pharmacies. (b) Tokishakuyakusan (2.5 g). (c) Orento in a bottle, prepared for research at Kanazawa Medical University but not for use in hospitals or pharmacies. (d) Orento.
Metabolites 14 00003 g014
Metabolites 14 00003 g015
Figure 15. Schematic diagram of oral Kampo medicine administration in the body. Medicines are digested in the stomach, absorbed in the small intestine, metabolized in the liver, passed into the blood, and transported to various organs and tissues.
Figure 15. Schematic diagram of oral Kampo medicine administration in the body. Medicines are digested in the stomach, absorbed in the small intestine, metabolized in the liver, passed into the blood, and transported to various organs and tissues.
Metabolites 14 00003 g015
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Takata, T.; Masauji, T.; Motoo, Y. Analysis of Crude, Diverse, and Multiple Advanced Glycation End-Product Patterns May Be Important and Beneficial. Metabolites 2024, 14, 3. https://doi.org/10.3390/metabo14010003

AMA Style

Takata T, Masauji T, Motoo Y. Analysis of Crude, Diverse, and Multiple Advanced Glycation End-Product Patterns May Be Important and Beneficial. Metabolites. 2024; 14(1):3. https://doi.org/10.3390/metabo14010003

Chicago/Turabian Style

Takata, Takanobu, Togen Masauji, and Yoshiharu Motoo. 2024. "Analysis of Crude, Diverse, and Multiple Advanced Glycation End-Product Patterns May Be Important and Beneficial" Metabolites 14, no. 1: 3. https://doi.org/10.3390/metabo14010003

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop